期刊文献+

参麦注射液对扩张型心肌病sICAM-1水平的影响 被引量:4

Effect of Shenmai injection on sICAM-1 in patients with dilated cardiomyopathy
下载PDF
导出
摘要 目的探讨扩张型心肌病(DCM)的发病机制及参麦注射液对扩张型心肌病患者抗黏附治疗的有效性。方法用酶联免疫吸附法测定40例扩张型心肌病患者及25例健康对照组sICAM-1水平,并将DCM患者随机分为常规治疗组(20例)和参麦治疗组(20例),常规治疗组予常规治疗,参麦治疗组在常规治疗的基础上加用参麦注射液,同时监测治疗前后血清sICAM-1水平的变化。结果扩张型心肌病患者血清sICAM-1(121.21±43.55)ng/ml明显高于对照组(60.76±21.85)ng/ml(P<0.01);参麦治疗组sICAM-1水平由治疗前的(120.77±33.87)ng/ml下降到治疗后的(62.21±23.43)ng/ml;常规治疗组sICAM-1水平由治疗前的(121.64±52.40)ng/ml下降到治疗后的(95.99±24.65)ng/ml,但无统计学意义(P>0.05),且治疗后参麦治疗组sICAM1水平明显低于同期常规治疗组(P<0.05)。结论扩张型心肌病患者血清中sICAM-1高表达,参麦注射液能明显降低扩张型心肌病患者血清sICAM-1含量,具有抗黏附作用,能够抑制血管壁炎症、保护血管内皮细胞。 Objective To study the effect of Shenmai injection on sICAM-1 in patients with dilated cardiomyopathy. Methods With enzymelinked immunosorbent assay( ELISA), serum levels of soluble intercellular adhesion molecule- I(sICAM-1) was measured in the sera from 40 patients with dilated cardiomyopathy (DCM) and 25 healthy people. Forty patients were divided into two groups, including control group treated with conventional medicine (20 patients) and SMI group treated with conventional medicine plus SMI (20 patients), sICAM-1 was measured before and after treatment. Results sICAM- 1 in patients with DCM (121.21±43.55) ng/ml was increased compared with health people (60.76±21.85) ng/ml (P〈0.01). sICAM - I in SMI group after treatment(120.77±33. 87)ng/ml decreased more significantly than that before treatment(62.21±23.43). Conclusion Serum soluble intercellular adhesion molecule- 1 was high in patients with dilated cardiomyopathy. SMI can attenuate serum sICAM-1 in patients with dilated cardiomyopathy.
出处 《西部医学》 2009年第7期1127-1129,共3页 Medical Journal of West China
基金 安徽省教育厅自然科学研究项目(编号:KJ2007B140)
关键词 扩张型心肌病 细胞间黏附分子1 参麦注射液 Dilated cardiomyopathy Intercellular adhesion molecule- 1 Shenmai injection
  • 相关文献

参考文献2

二级参考文献12

  • 1陈前芬,田鹤邨,杨卫东,储德开.参麦注射液对局灶性脑缺血再灌注局部脑血流和脂质过氧化的影响[J].中国病理生理杂志,1996,12(4):440-440. 被引量:40
  • 2Mobini R, Maschke H, Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. Autoimmun Rev 2004;3(4):277-284.
  • 3Schwimmbeck PL, Badorff C, Rohn G, et al. The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Int J Cardiol 1996;54(2):117-125.
  • 4Rakozy CK, Mohamed AV, Vo TD, et al. CD56^+/CD4^+ lymphomas and leukemias are morphologically, innumophenotypocally, cytogenetically and clinically diverse. Am J Clin Pathol 2001;116(2):168-176.
  • 5Richardson CP, Mckenna RM, Bristow CM, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathy. Circulation 1996;93:841-842.
  • 6Staudt A, Staudt Y, Dorr M, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 2004;44(4):829-836.
  • 7全国心肌炎 心肌病专题研讨会组委会.全国心肌炎心肌病专题研讨会纪要[J].临床心血管病杂志,1995,11:324-326.
  • 8张可放,丁明,吴瑞婷,高孝斗,付方明.参麦注射液对冠心病患者抗氧化作用的影响[J].山东中医杂志,1997,16(7):300-301. 被引量:14
  • 9柳志红,程显声,张朝阳,赵彦芬,何建国,张云,倪新海,陈白屏.参麦注射液对充血性心力衰竭的疗效观察[J].中国中西医结合杂志,1998,18(4):212-213. 被引量:64
  • 10郭峰.红细胞免疫的研究和意义[J].自然杂志,2002,24(5):268-273. 被引量:35

共引文献19

同被引文献56

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部